Actylis opens API manufacturing facility in Oregon, US
The 30,000 sq ft facility will manufacture innovative APIs and excipients at both clinical trial and full commercial scale
Actylis | 08/03/2023 | By Sudeep Soparkar | 801
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy